WK: Resources, Conceptualization, Methodology, Writing review & editing, Writing original draft
Protein Cell 12(5):360373 Kessoku T, Imajo K, Kobayashi T, Ozaki A, Iwaki M, Honda Y et al (2020) Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial
Bacteriostatic water supports controlled reconstitution workflows, but compound specific stability should always be evaluated separately
Dihexa peptides have high affinity for binding to hepatocyte growth factor (HGF) and enhancing its activity on the receptor c-Met, which gives them unique advantages in improving skin condition and achieving cosmetic effects
It allows for easy administration and is ideal for localized treatment
Generation 2: Tirzepatide, dual-agonist GLP-1 + GIP Tirzepatide adds the glucose-dependent insulinotropic peptide (GIP) receptor to the GLP-1 target